rs1079128 — SLC2A9

Deeply intronic SLC2A9 variant at chromosome 4:9,949,597 (GRCh38) within the GLUT9 renal urate transporter locus; the T allele (GRCh38 reference) is common in East Asian populations (~92%) where gout prevalence is highest, while the C allele (~71% in Africans) tags a haplotype associated with more efficient renal urate clearance and lower serum uric acid setpoint

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 rs1079128 — An Intronic Tag of the GLUT9 Urate Transport Locus

The SLC2A9 gene on chromosome 4 encodes GLUT911 GLUT9
Glucose Transporter 9, a high-capacity urate transporter in the kidney proximal tubule responsible for reabsorbing uric acid from the tubular filtrate back into the bloodstream at rates 45–60-fold faster than glucose; it accounts for approximately 60% of total renal urate reabsorption. The SLC2A9 locus is the single largest genetic determinant of serum uric acid in humans, with multiple independent intronic signals collectively explaining up to 5–6% of urate variance in Europeans. rs1079128 sits deep within an intron of this gene — approximately 7,552 base pairs from the nearest exon boundary — at genomic coordinates chr4:9,949,597 (GRCh38 plus strand: NC_000004.12:g.9949597T>C).

What makes rs1079128 notable is its population distribution. The T allele (the GRCh38 reference) reaches its highest frequency in East Asian populations (~92%), the populations with the highest global burden of gout and hyperuricemia. The C allele, which appears to tag a haplotype associated with more efficient renal urate clearance, is most common in African populations (~71%). This cross-population gradient mirrors the pattern seen at other protective SLC2A9 intronic variants across the 4p16.1 locus, where the protective allele is consistently rarest in ancestries with the heaviest gout burden.

The Mechanism

rs1079128 is classified as an intron variant and does not alter any amino acid in the GLUT9 protein. Its biological significance, if any, is regulatory. Wei et al. (2014)22 Wei et al. (2014) demonstrated that the SLC2A9 locus harbours abundant local epistatic interactions, with intronic SNPs enriched at active enhancer elements in hepatic (HepG2) and erythroid (K562) cell lines. These enhancers plausibly regulate how much GLUT9 protein the kidney proximal tubule produces, thereby setting the efficiency of urate reabsorption without altering the transporter's structure. Because the variant lies ~7.5 kb from the nearest exon, it is more likely a tag SNP for a regulatory haplotype than a functional variant in its own right — but direct functional data are not yet available for rs1079128 specifically.

As with all SLC2A9 intronic variants, the anticipated effect on serum urate would be substantially larger in women than in men33 substantially larger in women than in men
Döring et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008, where estrogen independently stimulates fractional excretion of uric acid and amplifies the phenotypic contrast between genotypes (1.2% variance in men vs. up to 6% in women across the SLC2A9 locus).

The Evidence

SLC2A9 as the dominant urate locus: Vitart et al. (2008)44 Vitart et al. (2008) performed a genome-wide association scan in a Croatian island isolate and replicated in UK and German cohorts, identifying intronic SLC2A9 variants explaining 1.7–5.3% of serum urate variance — the largest single-gene effect on urate ever described. Functional experiments in Xenopus oocytes confirmed that GLUT9 transports urate with high capacity and specificity, establishing the biological mechanism underlying the GWAS signal.

Sex-specific amplification: Döring et al. (2008)55 Döring et al. (2008) used the KORA cohort (n = 1,644) with three independent European replication sets to show that SLC2A9 intronic variants reduce serum urate by −0.23 to −0.36 mg/dL per copy of the minor (protective) allele in men, and −0.36 to −0.46 mg/dL in women — with the gene explaining up to 6% of total urate variance in women but only 1.2% in men. The difference is attributed to estrogen's independent activation of renal urate excretion pathways, which disappears at menopause.

Large-scale GWAS meta-analysis: Kolz et al. (2009)66 Kolz et al. (2009) meta-analysed 28,141 Europeans across 14 cohort studies, confirming SLC2A9 as the dominant urate locus and demonstrating sex-differential effects at the lead SLC2A9 variant rs734553.

Multiple independent signals within the locus: Wei et al. (2014)77 Wei et al. (2014) showed using ARIC and Framingham Heart Study data that a model of five locally interacting SNPs in the 4p16.1 region explains 1.5% more urate variance than the single lead SNP alone, with epistatic interaction terms enriched at functional enhancers. This architecture — multiple partially independent intronic haplotypes each contributing to GLUT9 expression — provides the mechanistic context for rs1079128's potential role.

Important caveat: No publications in PubMed or the GWAS Catalog directly associate rs1079128 with serum uric acid or gout under its specific rsid. The risk directionality presented here is inferred from the SLC2A9 population-gradient pattern (T allele enrichment in high-gout East Asian populations, C allele enrichment in lower-gout African populations). The evidence level is therefore emerging rather than moderate or higher. Direct genotype-phenotype studies are needed to confirm the risk allele assignment.

Practical Actions

Because rs1079128 sits in the same SLC2A9 locus as well-characterised urate variants, the same dietary and monitoring principles apply when interpreting the T/T genotype. The most actionable interventions come from fructose avoidance (which amplifies SLC2A9 risk genotype effects via direct competition for renal urate transporters and hepatic urate production) and baseline serum uric acid monitoring.

Women who carry T alleles should pay particular attention around menopause — the loss of estrogen's uricosuric effect can unmask a genetic urate elevation that was previously buffered. Low-fat dairy products, coffee, and vitamin C have modest but evidence-based urate-lowering effects relevant across SLC2A9 risk genotypes.

Interactions

With rs11942223 and rs3733591 (same gene, independent signals): The SLC2A9 gene contains at least three genetically independent signals: the coding variant rs3733591 (Arg265His), the intronic signal rs11942223, and the broader 4p16.1 haplotype complex. rs1079128 at chr4:9,949,597 is ~11.5 kb from rs11942223 (chr4:9,961,141) — a separation that places them in potentially distinct LD blocks. Individuals carrying risk alleles at multiple SLC2A9 variants accumulate additive urate burden from independent mechanisms.

With ABCG2 rs2231142 (Q141K): ABCG2 governs intestinal urate secretion, a distinct pathway from the renal reabsorption controlled by SLC2A9. Carrying SLC2A9 T alleles (reduced renal excretion) alongside ABCG2 rs2231142 risk alleles (reduced gut efflux) compounds urate retention through two independent routes and can push steady-state serum uric acid above 7 mg/dL in otherwise healthy individuals.

Fructose gene-environment interaction: Dalbeth et al. (2013)88 Dalbeth et al. (2013) showed that SLC2A9 genotype modulates the acute urate spike after a 64-gram fructose load — a finding that applies to the entire SLC2A9 locus and makes sugar-sweetened beverage restriction the highest-leverage dietary action for T allele carriers.

Nutrient Interactions

fructose altered_metabolism
purines altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Efficient Urate Clearance Normal

Two C alleles — lower urate setpoint, favorable SLC2A9 haplotype

You carry two copies of the C allele at rs1079128. Based on the population-gradient pattern at the SLC2A9 locus, the C allele appears to tag a haplotype associated with more efficient renal urate excretion through GLUT9. This genotype is uncommon in East Asian populations (~4% CC frequency by Hardy-Weinberg) where gout prevalence is highest, and most common in African populations (~50% CC frequency). Your genetic risk for hyperuricemia from this specific SLC2A9 signal appears favorable. Because rs1079128 lacks direct GWAS evidence, this interpretation is based on the locus-level SLC2A9 population gradient rather than a directly measured genotype-phenotype association.

CT Intermediate Urate Risk Intermediate

One C, one T allele — intermediate SLC2A9 urate-transport signal

Direct GWAS data for rs1079128 are not published, so the intermediate risk interpretation is inferred from the broader SLC2A9 locus pattern. The CT genotype at heterozygous SLC2A9 intronic variants typically produces approximately half the urate elevation of TT homozygotes, based on the additive architecture documented at nearby variants (rs11942223, rs4473653, and the lead GWAS SNP rs734553). For context, a single T-allele dose at well-characterised SLC2A9 intronic variants raises serum urate by approximately 0.10–0.20 mg/dL — a modest but clinically meaningful increment when combined with other genetic and dietary urate contributors. Women who carry CT and are post-menopausal lose the estrogen-driven uricosuric buffer and should monitor serum uric acid proactively.

TT Elevated Urate Risk High Risk

Two T alleles — highest genetic urate signal at this SLC2A9 locus

Direct GWAS associations for rs1079128 are not published as of April 2026; the risk directionality here is inferred from the SLC2A9 locus-level population gradient and the consistent pattern across multiple independent intronic SLC2A9 signals. At well-characterised SLC2A9 intronic variants with similar allele frequency patterns, TT homozygotes show serum urate approximately 0.20–0.46 mg/dL above CC homozygotes, with the larger effect in women and at post-menopausal status.

If you also carry risk alleles at rs11942223 (another independent intronic signal), rs3733591 (Arg265His coding variant), or ABCG2 rs2231142 (intestinal urate secretion), each locus adds independently to the urate burden — and the combination can push serum urate above 7 mg/dL even without exceptional dietary purine loading.

Sugar-sweetened beverage consumption is particularly important to address in TT carriers: fructose directly raises urate through hepatic production while also competing for renal tubular urate transporters, amplifying any genetically elevated urate setpoint.